Intravenous branched-chain amino acid administration for the acute treatment of hepatic encephalopathy: a systematic review and meta-analysis
Authors' conclusion
Our meta-analysis demonstrates that all outcomes were not significantly different between IV-BCAA treatment and placebo for acute HE.
Study context
- Population
- Adults with acute hepatic encephalopathy
- Participants
- 219 adults · 4 randomized controlled trials (RCTs)
- Comparison
- Intravenous BCAA (IV-BCAA) vs placebo
- IV-BCAAn = 109
- Placebon = 110reference
- Outcome
- Mortality from any cause and improvement in disturbance of consciousness
Methodological detailsrandom effects models with inverse variance weighting
- Random effects models with inverse variance weighting
Pooled result
As reported in the abstract
IV-BCAA vs PlaceboRelative risk (95% CI)
Improvement in disturbance of consciousness; 118 more per 1000 (95% CI 18 fewer-300 more)
1.26(0.96–1.66)
Mortality; 55 fewer per 1000 (95% CI 165 fewer-88 more)
0.90(0.70–1.16)
Safety
Nausea or diarrhea
- No significant differences between the two groups
Original publication
Intravenous branched-chain amino acid administration for the acute treatment of hepatic encephalopathy: a systematic review and meta-analysis. J Intensive Care. Published 9 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →